Supplementary file 1_Tenecteplase in acute ischemic stroke: an updated meta-analysis.docx

This study aimed to evaluate the efficacy and safety of TNK compared with tPA.</p>Methods<p>Following the PRISMA 2020 guidelines, PubMed, Web of Science, Cochrane Central, EBSCO, and Scopus were systematically searched from inception through January 2026 to identify randomized controlled trials (RCTs) and observational studies comparing TNK with tPA in adults with AIS.

Effect estimates were pooled using fixed- or random-effects models according to the degree of heterogeneity and were reported as risk ratios (RRs), odds ratios (ORs), or mean differences (MDs) with 95% confidence intervals (CIs).</p>Results<p>Twenty-four studies (6 RCTs and 18 observational studies; total n = 20,592) involving patients with AIS were included. Compared with tPA, TNK was associated with a greater likelihood of excellent functional recovery (mRS 0–1) at 90 days (RR = 1.08; 95% CI: 1.01–1.15; p = 0.02) and a shorter door-to-needle time by an average of 4 min (MD = −4.20; 95% CI: −7.77 to −0.64; p = 0.02).